Erlotinib Completed Phase 2 Trials for Stage IV Pancreatic Cancer / Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01222689Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT01389440Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer